EcoDrugPlus

Toll Like Receptor 2

Ensembl ID : ENSCPRG00005009198
Gene Symbol: TLR2
2 Cross references
244 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Toll Like Receptor 4

Ensembl ID : ENSCPRG00005013883
Gene Symbol: TLR4
1 Cross references
126 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Toll Like Receptor 7

Ensembl ID : ENSCPRG00005006334
Gene Symbol: TLR7
1 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Toll-Like Receptor 8

Ensembl ID : ENSCPRG00005006332
Gene Symbol: LOC109306065
2 Cross references
189 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Trace Amine Associated Receptor 1

Ensembl ID : ENSCPRG00005005653
Gene Symbol: TAAR1
3 Cross references
600 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transforming Growth Factor Beta Receptor 1

Ensembl ID : ENSCPRG00005013433
Gene Symbol: TGFBR1
3 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily A Member 1

Ensembl ID : ENSCPRG00005018361
Gene Symbol: TRPA1
3 Cross references
228 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily M Member 8

Ensembl ID : ENSCPRG00005005682
Gene Symbol: TRPM8
3 Cross references
158 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily V Member 1

Ensembl ID : ENSCPRG00005013113
Gene Symbol: TRPV1
3 Cross references
134 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Translocator Protein

Ensembl ID : ENSCPRG00005003074
Gene Symbol: TSPO
3 Cross references
122 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transthyretin

Ensembl ID : ENSCPRG00005015105
Gene Symbol: TTR
4 Cross references
167 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Trifunctional Purine Biosynthetic Protein Adenosine-3-Like

Ensembl ID : ENSCPRG00005014597
Gene Symbol: LOC109305783
2 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).